301 related articles for article (PubMed ID: 34439854)
1. BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme.
Xavier MA; Rezende F; Titze-de-Almeida R; Cornelissen B
Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439854
[TBL] [Abstract][Full Text] [Related]
2. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
Cerrato A; Morra F; Celetti A
J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
[TBL] [Abstract][Full Text] [Related]
3. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
[TBL] [Abstract][Full Text] [Related]
4. Defining and Modulating 'BRCAness'.
Byrum AK; Vindigni A; Mosammaparast N
Trends Cell Biol; 2019 Sep; 29(9):740-751. PubMed ID: 31362850
[TBL] [Abstract][Full Text] [Related]
5. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
6. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
Voutsadakis IA; Stravodimou A
Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
[TBL] [Abstract][Full Text] [Related]
7. Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness.
Darbeheshti F; Kadkhoda S; Keshavarz-Fathi M; Razi S; Bahramy A; Mansoori Y; Rezaei N
BMC Cancer; 2022 Jun; 22(1):668. PubMed ID: 35715772
[TBL] [Abstract][Full Text] [Related]
8. [BRCA1 and BRCA2 - pathologists starting kit].
Škapa P
Cesk Patol; 2016; 52(4):193-196. PubMed ID: 27869444
[TBL] [Abstract][Full Text] [Related]
9. DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation.
Abbotts R; Topper MJ; Biondi C; Fontaine D; Goswami R; Stojanovic L; Choi EY; McLaughlin L; Kogan AA; Xia L; Lapidus R; Mahmood J; Baylin SB; Rassool FV
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22609-22618. PubMed ID: 31591209
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the methods to identify patients who may benefit from PARP inhibitor use.
Lim D; Ngeow J
Endocr Relat Cancer; 2016 Jun; 23(6):R267-85. PubMed ID: 27226207
[TBL] [Abstract][Full Text] [Related]
11. PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.
Risdon EN; Chau CH; Price DK; Sartor O; Figg WD
Oncologist; 2021 Jan; 26(1):e115-e129. PubMed ID: 32790034
[TBL] [Abstract][Full Text] [Related]
12. BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality.
Murai J; Pommier Y
Cancer Res; 2023 Apr; 83(8):1173-1174. PubMed ID: 37057596
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J
Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061
[TBL] [Abstract][Full Text] [Related]
14. BRCA1/2 testing: therapeutic implications for breast cancer management.
Tung NM; Garber JE
Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
[TBL] [Abstract][Full Text] [Related]
15. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
[TBL] [Abstract][Full Text] [Related]
16. A Novel Mechanism to Induce BRCAness in Cancer Cells.
Cai C
Cancer Res; 2020 Jul; 80(14):2977-2978. PubMed ID: 32669350
[TBL] [Abstract][Full Text] [Related]
17. Exploiting replication gaps for cancer therapy.
Cong K; Cantor SB
Mol Cell; 2022 Jul; 82(13):2363-2369. PubMed ID: 35568026
[TBL] [Abstract][Full Text] [Related]
18. Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies.
Stok C; Kok YP; van den Tempel N; van Vugt MATM
Nucleic Acids Res; 2021 May; 49(8):4239-4257. PubMed ID: 33744950
[TBL] [Abstract][Full Text] [Related]
19. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.
Lee JM; Ledermann JA; Kohn EC
Ann Oncol; 2014 Jan; 25(1):32-40. PubMed ID: 24225019
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade.
Chen T; Yu T; Zhuang S; Geng Y; Xue J; Wang J; Ai L; Chen B; Zhao Z; Li Y; Wang J; Liang H; Xu Y; Gu Y
Br J Cancer; 2022 Sep; 127(5):916-926. PubMed ID: 35618786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
